Afamelanotide vs GHK-Cu.

Afamelanotide is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), historically studied under the research name Melanotan I. It is formulated as a slow-release bioresorbable implant (Scenesse, Clinuvel) placed subcutaneously roughly every two months. Its approved use is not cosmetic tanning but photoprotection: increasing the amount of pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare inherited condition causing severe phototoxic pain. It is one of the very few peptide analogs of alpha-MSH to complete formal Phase 3 development and gain regulatory approval. It is grouped under cosmetic here only because it acts on skin pigmentation pathways; clinically it is a photoprotective orphan drug.

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide with the sequence glycyl-L-histidyl-L-lysine. GHK was first isolated from human plasma by Loren Pickart in the early 1970s and also occurs in saliva and urine; it binds copper ions with high affinity to form the violet-colored GHK-Cu complex. The free peptide sequence is embedded within the alpha-2 chain of type I collagen, and it is thought to be liberated during tissue injury, making it a candidate endogenous signal of tissue damage and repair. It is best known as a cosmetic ingredient and a widely studied "copper peptide."

Afamelanotide is an agonist at melanocortin-1 receptors (MC1R) on epidermal melanocytes. Activating MC1R stimulates production of eumelanin, the darker, more photoprotective form of melanin, independent of ultraviolet exposure. Increased eumelanin absorbs and scatters visible and UV light, reducing the free-radical and phototoxic response that causes pain in EPP, where protoporphyrin IX accumulates and is activated by light. The analog is more potent and longer-acting than native alpha-MSH because of amino-acid substitutions that resist enzymatic degradation. Additional antioxidant and anti-inflammatory melanocortin effects have been proposed but are less well characterized.

GHK is a copper-coordinating molecule: the glycine amino terminus, the histidine imidazole, and a deprotonated peptide nitrogen form a square-planar Cu(II) chelate, a geometry confirmed by X-ray and solution-structure studies, allowing GHK to shuttle copper to and from cells and to modulate copper's redox chemistry. Beyond copper transport, GHK-Cu has been reported to stimulate fibroblast synthesis of collagen, elastin, glycosaminoglycans, and proteoglycans while modulating matrix metalloproteinases, consistent with a role in dermal remodeling. Bioinformatic analysis using the Broad Institute Connectivity Map found that GHK alters the expression of a large fraction of assayed human genes in cultured cells (upregulating some and suppressing others), including genes tied to antioxidant defense, anti-inflammatory signaling, DNA repair, and tissue regeneration. It has also shown antioxidant behavior in vitro, including blocking copper-dependent oxidation of low-density lipoprotein.

Approval rested on randomized, placebo-controlled trials in EPP. In the pivotal randomized controlled trial published in the New England Journal of Medicine (Langendonk, Balwani et al., 2015), patients receiving afamelanotide implants recorded more total hours of pain-free sunlight exposure than those on placebo across parallel European and U.S. studies. The FDA summary describes a European trial in which the afamelanotide group spent roughly 64 hours in direct midday sunlight on pain-free days versus about 41 hours for placebo over 180 days, with a second study of similar design over 270 days. Effect sizes were statistically significant but modest in absolute terms, and outcomes relied on patient-recorded diaries. Long-term extension and post-marketing data continue to track durability and safety. The design carries specific caveats. Both pivotal studies were sponsored by the manufacturer, enrolled small populations because EPP is a rare disease, and used a patient-reported diary of time in sunlight as the primary endpoint rather than an objective measurement of light exposure or an adjudicated clinical outcome. Blinding is difficult to maintain with an agent whose visible effect is skin darkening, so participants and investigators could often infer allocation, a recognized source of bias in subjective endpoints. Later work has tried to address the measurement problem directly by recording light exposure objectively in EPP patients (Molecular Genetics and Metabolism, 2022). Pharmacokinetic and pharmacodynamic characterization of the implant and its dermatologic uses has been reviewed separately (Clinical Pharmacokinetics, 2017). What the EPP approval establishes is narrow. It shows that a slow-release implant of a stable alpha-MSH analog, given under physician supervision to adults with a specific inherited photosensitivity disorder, increases self-reported pain-free daylight time versus placebo over months. It does not establish efficacy or safety for cosmetic tanning, for skin cancer prevention, for any other photosensitivity condition, or for self-administered injectable products. Evidence for the widely marketed tanning use of Melanotan I is not from these regulated trials and is not supported to the same standard. Melanotan II, a different and unapproved analog sold online, has never completed a comparable regulated program at all.

The strongest human evidence is cosmetic/dermatologic: small topical studies of GHK-Cu-containing creams have reported improvements in skin appearance, density, and wrinkles, but these are generally short, small, and often industry-adjacent rather than large randomized therapeutic trials. Much of the mechanistic case rests on in vitro and animal work (fibroblast cultures, rodent and rabbit wound-healing models, and rat nerve-regeneration experiments), plus gene-expression analyses (Pickart & Margolina, Int J Mol Sci 2018; Pickart et al., BioMed Res Int 2015). A notable bioinformatic finding is that GHK was computationally identified, via Connectivity Map screening of a human COPD lung gene signature, as a compound predicted to reverse that disease-associated expression pattern (Meiners & Eickelberg, Genome Medicine 2012), but this was a transcriptomic prediction, not a clinical trial, and GHK was not administered to patients. There are no large controlled human trials supporting injected/systemic GHK-Cu for anti-aging, organ repair, or the regenerative claims often made online; that gap between mechanistic plausibility and proven clinical benefit is wide.

In EPP trials the most common adverse effects were implant-site reactions, headache, nausea, fatigue, and darkening of skin and pre-existing moles (expected from increased melanin). Because it drives pigmentation, regular full-skin and mole monitoring is advised, and the drug does not itself protect against UV-induced skin cancer. The trials that supported approval were small and ran for months rather than years, so long-term questions remain open: whether sustained melanocortin receptor stimulation influences melanocytic lesion behavior or melanoma risk over decades has not been resolved, which is one reason dermatologic surveillance is built into how the implant is used. Reviews of eruptive melanocytic nevi discuss the range of reported triggers, including drug exposures, and illustrate why new or changing pigmented lesions are treated as a monitoring priority in this setting. Unregulated Melanotan products sold online for tanning are a distinct safety concern: they are not the approved implant, may be contaminated or mis-dosed, and injectable use has been linked in case reports to nausea, blood-pressure changes, and changes in moles. These products bypass every control that applies to the licensed implant, which is manufactured to pharmaceutical standards, inserted by a trained physician, and dispensed only through certified prescribers under a specific rare-disease indication. Melanotan II in particular is an unapproved compound with no completed regulated trial program, sold with no verified content or sterility, and case reports describing adverse events after its use exist in the dermatology literature. This entry is educational and does not provide dosing guidance.

In topical cosmetic use GHK-Cu has a long track record and is generally well tolerated, with the main reported issues being local irritation, redness, or contact sensitivity in some users. The safety of injected or systemic GHK-Cu in humans is not established by rigorous clinical study, and because the molecule carries copper, concerns about copper loading and pro-oxidant copper redox chemistry are biologically plausible and not well characterized for non-topical use. Purity, sterility, and actual copper content of research-grade or compounded products are unverified and vary by supplier. Overall, human safety data outside cosmetic topical contexts is thin, and unknowns dominate.

The FDA approved Scenesse (afamelanotide) in October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, with Orphan Drug and Priority Review designations; the European Medicines Agency had authorized it earlier (2014). It is a prescription implant administered by a trained physician. Melanotan-branded tanning products are not approved and are considered unapproved drugs in many jurisdictions.

GHK-Cu is not an FDA-approved drug; it is used as a cosmetic skincare ingredient (where cosmetic ingredients are not FDA pre-approved) and is otherwise sold for research/investigational purposes. It is not an approved therapeutic for wound healing, anti-aging, or any systemic indication, and it is not currently a WADA-prohibited substance.